Version classiqueVersion mobile
OpenEdition Books

Lutte contre le trachome en Afrique subsaharienne

Anne-Marie Moulin
Jeanne Orfila
Doulaye Sacko
et al.

Part One. Synopsis and recommendations. English Version

Appendix 1. Specifications for the expert group review

Texte intégral


Question 1

“How can we identify persons or communities at risk from trachoma and its blinding complications? (Risk factors, geographical distribution of the risks, risky behavior, risk markers)?”

Question 2

“What is the role of ”mother and child“ in the transmission of trachoma? How does the primary infection appear in the young child: how can we reduce or prevent this way of infection? ”

Question 3

“What are the epidemiological models for predicting the elimination of blinding trachoma between now and 2020?”

Question 4

“How can we evaluate the rate of blindness preventable by curing trichiasis?”

Question 5

“How can we evaluate the effectiveness of azithromycin? (Evaluation methods, documented experiments, short and long-term effectiveness on public health)”

Question 6

“What are the positive and negative effects of antibiotic therapy, distributed extensively, on other pathologies and on the health of the population receiving it?”

Question 7

“What are the most adequate surveillance methods for guiding trachoma control?”

Question 8

“What are the intervention and cure thresholds?” “What will be the long and medium-term roles of geographic informa­tion systems (GIS)?”


Question 9

“Trachoma, present before the last world war in very many countries of the north and south, has disappeared from these countries. What are the historical, social, cultural and medical determinants explaining this disap­pearance and its persistence in other countries?”

Question 10

“Are there any examples where blinding trachoma has disappeared from regions with endemic disease without a significant improvement in the socio-economic level?”

Question 11

“What are the signs of trachoma and is there a link between conjunc­tivitis and trichiasis for the population?”

Question 12

“How can we guide traditional practitioners so that they play a role in changing behavior, especially in the mother and child couple?”

Question 13

“How can we mobilize society, especially women, to combat trachoma?”

Question 14

“Can the reduction in blinding trachoma be used as an indicator of development in regions of endemic disease?”

Question 15

“What are the economic consequences of trachoma and what is the economic impact of intervention in this field?”

Question 16

“Can hygiene education and its application within schools help to improve hygiene in the families and the village?”

Question 17

“How can the provision of water improve protection against trachoma? (Quantity, quality, proximity, method of use)”

Question 18

“What are the general hygiene measures most relevant for preventing trachoma?”

Question 19

“What can we expect from sanitation and fly control in the prevention of trachoma?”


Question 20

“When and how can we operate on trichiasis (indications, quality, delegation, rate of cover, strategy)?”

Question 21

“Are there traditional substances used in eye infections which are active against trachoma? What is the impact of traditional practices on the evolution of trachoma?”

Question 22

“What national strategies should be developed to make azithromycin accessible and how can we ensure continued distribution?”

Question 23

“What are the consequences of mass distribution (reference to praziquantel and ivermectin) on the health system?”

Question 24

“What is the risk of azithromycin being diverted for use on other diseases and how can we prevent it?”

Question 25

“Can the S, A and F components of the SAFE strategy be integrated in the health system?”

Question 26

“Are there any successful cases of the SAFE strategy being adopted by the community?”

“Are there any community-based initiatives to strengthen the war on trachoma?”

© IRD Éditions, 2006

Conditions d’utilisation :